Mutations in the RAS gene family are present in about 20% of human cancers and directly contribute to the development of these cancers.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Mutations in the RAS gene family are present in about 20% of human cancers and directly contribute to the development of these cancers.
See the technical phrasing
The RAS gene family directly drives oncogenesis in approximately 20% of all human cancers.
A faulty version of the RAS protein stays permanently switched on, sending constant growth signals that make cells divide nonstop and avoid death. This happens through two main pathways: one that turns on proteins like ERK to speed up cell division, and another that activates AKT and mTOR to keep cells alive and fuel their growth. These signals overwhelm normal controls, turning healthy cells into cancer cells.
What the research says
Supports
3 studies
Study: Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies